MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Home・Akcijų sąrašas・Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

76.33 -1.14

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

74.52

Max

77.84

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-252M -129M
Pardavimai	-295M 157M
Pelno marža	-82.062
Darbuotojai	1,069
EBITDA	-245M -94M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+22.94% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-02-18

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	1.6B 13B
Ankstesnė atidarymo kaina	77.47
Ankstesnė uždarymo kaina	76.33

Naujienos nuotaikos

By Acuity

50%

159 / 361 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

29.78 / 33.645 Palaikymas ir pasipriešinimas

Ionis Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-16 23:29; UTC

Karštos akcijos

Stocks to Watch: Atossa Therapeutics, Union Pacific

2026-01-16 22:48; UTC

Įsigijimai, susijungimai, perėmimai

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- 2nd Update

2026-01-16 22:43; UTC

Įsigijimai, susijungimai, perėmimai

Union Pacific: Additional Information Requested to Be Provided to Surface Transportation Board

2026-01-16 22:22; UTC

Įsigijimai, susijungimai, perėmimai

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- Update

2026-01-16 21:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2026-01-16 21:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Auto & Transport Roundup: Market Talk

2026-01-16 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-01-16 21:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-01-16 21:48; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Union Pacific, Norfolk Southern Market Share Ruled as Faulty -- Market Talk

2026-01-16 21:41; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Union Pacific, Norfolk Southern Deal Rejection Leaves Questions -- Market Talk

2026-01-16 21:38; UTC

Įsigijimai, susijungimai, perėmimai

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- WSJ

2026-01-16 21:30; UTC

Įsigijimai, susijungimai, perėmimai

STB: Union Pacific, Norfolk Southern Application Doesn't Include 'Projected Market Shares' as Required

2026-01-16 21:30; UTC

Įsigijimai, susijungimai, perėmimai

STB: Union Pacific, Norfolk Southern Application Doesn't Include Certain Schedules, Documents Expressly Made Part of Merger Agreement

2026-01-16 21:30; UTC

Įsigijimai, susijungimai, perėmimai

STB: Union Pacific, Norfolk Southern Application Doesn't Contain Certain Information Required by Regulations

2026-01-16 21:30; UTC

Įsigijimai, susijungimai, perėmimai

STB: Application Rejected Without Prejudice to Union Pacific, Norfolk Southern Refiling Revised Application Remedying Deficiencies

2026-01-16 21:30; UTC

Įsigijimai, susijungimai, perėmimai

Surface Transportation Board: Union Pacific, Norfolk Southern Major Merger Application Filed Dec. 19 Incomplete

2026-01-16 20:44; UTC

Uždarbis

5 Takeaways From This Season's Wealth Management Earnings -- Barrons.com

2026-01-16 20:42; UTC

Rinkos pokalbiai

Oil Futures Post Fourth Straight Weekly Gain -- Market Talk

2026-01-16 20:28; UTC

Rinkos pokalbiai

U.S. Natural Gas Slips Ahead of Long Weekend -- Market Talk

2026-01-16 19:12; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Netflix Could Comment on Structure of Warner Bid During 4Q Results -- Market Talk

2026-01-16 18:53; UTC

Rinkos pokalbiai

Global Crude Supply Enough to Absorb Any Iran Disruption -- Market Talk

2026-01-16 18:41; UTC

Rinkos pokalbiai

Netflix's Ad Business Seen as Primary Revenue Driver in 2026 -- Market Talk

2026-01-16 18:31; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Rises By 1 to 410 -- Market Talk

2026-01-16 17:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-01-16 17:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-01-16 17:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-01-16 17:03; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-01-16 17:03; UTC

Rinkos pokalbiai

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

2026-01-16 16:32; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Sanofi Needs Dealmaking to Offset Pipeline Disappointments -- Market Talk

2026-01-16 16:20; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Ionis Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

22.94% į viršų

12 mėnesių prognozė

Vidutinis 94.92 USD 22.94%

Aukščiausias 110 USD

Žemiausias 77 USD

Remiantis 14 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ionis Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

14 ratings

Pirkti

Laikyti

Parduoti

Remiantis 14 analitikų, pateikusių Ionis Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

29.78 / 33.645Palaikymas ir pasipriešinimas

The bullish and bearish events are balanced.

All events are bullish.

All events are bearish.

Rinkos nuotaikos

By Acuity

159 / 361 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.